Published: Jeffrey Cummings

Dr. Jeffrey Cummings (Brain Health) recently published an article, “The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs," in the Journal of Prevention of Alzheimer’s Disease. The somewhat provocative findings note that despite the trend toward prevention trials becoming more likely (in part because trials in later stages of the disease have failed) they lack many of the essential aspects of successful clinical trials including a well defined target, enough decline in a placebo group, biomarkers to predict a clinical effect, and an interested market if the therapeutic agent works. Cummings concludes, "trials in patients with symptoms have a better chance of success in drug development trials than prevention trials." 

People in the News

A man stands next to a stone wall
People | October 22, 2020
Outstanding Alumnus of the Year didn't let a little thing like Nevada's only law school closing stop him from pursuing a legal education.
A man leands against a wall with his arms folded
People | October 21, 2020
Silver State Award-winner Larry Ruvo is still charging hard into philanthropy, just like he has for more than 40 years.
woman in doctor's coat
People | October 21, 2020
Experiencing a sports injury in high school prompted Laura Wozniak to change career paths.